Real-world efficacy and safety of nivolumab for advanced non–small-cell lung cancer: a retrospective multicenter analysis

K Kobayashi, I Nakachi, K Naoki, R Satomi… - Clinical lung cancer, 2018 - Elsevier
Background Nivolumab, an immune checkpoint inhibitor, is now a standard treatment for
previously treated advanced non–small-cell lung cancer based on the results from phase III …
被引用次数：54 相关文章

Real-world Efficacy and Safety of Nivolumab for Advanced Non–Small-cell Lung Cancer: A Retrospective Multicenter Analysis

K Kobayashi, I Nakachi, K Naoki… - Clinical Lung …, 2018 - clinical-lung-cancer.com
Background Nivolumab, an immune checkpoint inhibitor, is now a standard treatment for
previously treated advanced non–small-cell lung cancer based on the results from phase III …

[引用][C] Real-world Efficacy and Safety of Nivolumab for Advanced Non–Small-cell Lung Cancer: A Retrospective Multicenter Analysis

K Kobayashi, I Nakachi, K Naoki, R Satomi… - Clinical Lung …, 2018 - cir.nii.ac.jp
Real-world Efficacy and Safety of Nivolumab for Advanced Non–Small-cell Lung Cancer: A
Retrospective Multicenter Analysis | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis

K Kobayashi, I Nakachi, K Naoki… - Clinical lung …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Nivolumab, an immune checkpoint inhibitor, is now a standard treatment for
previously treated advanced non-small-cell lung cancer based on the results from phase III …

Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis.

K Kobayashi, I Nakachi, K Naoki, R Satomi… - Clinical Lung …, 2018 - europepmc.org
Background Nivolumab, an immune checkpoint inhibitor, is now a standard treatment for
previously treated advanced non-small-cell lung cancer based on the results from phase III …